dianhydro-3,4-diacetylgalactitol has been researched along with carmustine in 1 studies
*Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) [MeSH]
*Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gál, F; Institóris, E; Otvös, L; Szikla, K | 1 |
1 other study(ies) available for dianhydro-3,4-diacetylgalactitol and carmustine
| Article | Year |
|---|---|
Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carmustine; Cross-Linking Reagents; Dianhydrogalactitol; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Leukemia L1210; Mice; Sugar Alcohols | 1989 |